VKH
VIRX

Virtu KCG Holdings’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Virtu KCG Holdings’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$208K Buy
+2,197
New +$252K 0.01% 2128
2017
Q1 		– Sell
-373
Closed -$47K – 3849
2016
Q4 		$47K Sell
373
-135
-27% -$18.8K ﹤0.01% 3100
2016
Q3 		$78K Buy
508
+354
+230% +$50K ﹤0.01% 2698
2016
Q2 		$18K Sell
154
-56
-27% -$6.2K ﹤0.01% 2811
2016
Q1 		$24K Buy
210
+154
+275% +$23.3K ﹤0.01% 2573
2015
Q4 		$11K Sell
56
-428
-88% -$80.1K ﹤0.01% 3363
2015
Q3 		$82K Buy
+484
New +$175K ﹤0.01% 2884
2015
Q2 		– Sell
-62
Closed -$32K – 3837
2015
Q1 		$32K Buy
62
+4
+7% +$2.02K ﹤0.01% 2895
2014
Q4 		$31K Buy
58
+2
+4% +$901 ﹤0.01% 3538
2014
Q3 		$84K Buy
+56
New +$81.1K ﹤0.01% 3229
2014
Q1 		– Sell
-96
Closed -$95K – 4183
2013
Q4 		$95K Buy
96
+47
+96% +$48.6K ﹤0.01% 3453
2013
Q3 		$51K Buy
+49
New +$52.4K ﹤0.01% 3506

Other funds holding VIRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Virtu KCG Holdings's VIRX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2017: 2,197 shares worth $208K. The stake represents 0.01% of the portfolio and ranks #2128 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in VIRX as recently as Q4 2016.

Virtu KCG Holdings first reported a position in VIRX in Q3 2013 and has held it in 12 quarters since. 37 funds tracked by Wall St. Rank hold VIRX as of Q2 2017.

  • Virtu KCG Holdings held 2,197 shares of Viracta Therapeutics, Inc. Common Stock worth $208K as of Q2 2017.
  • Viracta Therapeutics, Inc. Common Stock was a new Virtu KCG Holdings position in Q2 2017.
  • Viracta Therapeutics, Inc. Common Stock made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2128 holding.
  • Virtu KCG Holdings first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and has held it in 12 quarters since.
  • 37 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.